Regulus Therapeutics reported $2.47M in Selling and Administration Expenses for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Selling And Administration Expenses Change
Alnylam Pharmaceuticals ALNY:US $ 169.98M 15.51M
AstraZeneca AZN:LN 268.26B 35.48B
Astrazeneca AZN:US 3.27B 209M
Biogen BIIB:US $ 572.6M 62.3M
Celldex Therapeutics CLDX:US $ 7.15M 243K
Gilead Sciences GILD:US $ 1.36B 274M
GlaxoSmithKline GSK:LN 195.5B 18.5B
Intercept Pharmaceuticals ICPT:US $ 39.98M 10.02M
Intrexon XON:US $ 12.67M 6.91M
Lexicon Pharmaceuticals LXRX:US 10.69M 2.19M
Ligand Pharmaceuticals LGND:US $ 29.17M 10.99M
Merk MRK:US $ 2.42B 118M
Omeros OMER:US $ 13.92M 2.96M
Regulus Therapeutics RGLS:US $ 2.47M 423K
Sangamo Biosciences SGMO:US $ 15.09M 185K
Spectrum Pharmaceuticals SPPI:US $ 9.38M 485K
Takeda 4502:JP 231.48B 8.05B
Vital Therapies VTL:US $ 4.07M 82K
YTE INCY:US $ 253.28M 43.69M